{"schema":"hottub-news/story/v1","story":"st_zeocoptiqmvsi7kbx72q","title":"Jaypirca approval expanded to include treatment-naive CLL, small lymphocytic lymphoma","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/jaypirca-approval-expanded-to-include-treatment-naive-cll-small-zeocoptiqm","count":1,"items":[{"id":"n_zeocoptiqmvsi7kbx72q","seq":1431947,"kind":"article","title":"Jaypirca approval expanded to include treatment-naive CLL, small lymphocytic lymphoma","url":"https://www.healio.com/news/hematology-oncology/20261002/jaypirca-approval-expanded-to-include-treatmentnaive-cll-small-lymphocytic-lymphoma","summary":"The FDA expanded the approval of pirtobrutinib to include initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion. Pirtobrutinib (Jaypirca, Eli Lilly & Co.) — a selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor — already had been approved for patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) who already received a BTK inhibitor. It also is approved for certain patients…","published":"2026-10-02T20:59:07Z","seen":"2026-10-02T21:20:29Z","lang":"en","source":{"id":"kite-healio-com-23151b","name":"healio.com","domain":"healio.com"},"via":"kite-healio-com-23151b","topics":["medicine"],"authors":["Mark Leiser"],"entities":[{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q1088156","name":"chronic lymphocytic leukemia","type":"other"}],"mentions":2,"story":"st_zeocoptiqmvsi7kbx72q","category":"health","category_p":0.7099999785423279,"sentiment":"neutral","tone":0.3199999928474426,"political":0.10000000149011612}]}